BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33636496)

  • 1. Generation of an iPSC line (ZZUNEUi016-A) derived from a hypertrophic cardiomyopathy patient with the heterozygote mutation in MYH7 gene.
    Guo G; Fu W; Li X; Dong J; Zhao X; Zhang Y
    Stem Cell Res; 2021 May; 53():102262. PubMed ID: 33636496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of a hiPSC line ZZUNEUi007-A from a patient with hypertrophic cardiomyopathy caused by mutation in MYH7.
    Li X; Liu Y; Liu F; Wang X; Liu M; Du W; Zhao J; Wang M; Hu L; Wang C; Fu W; Dong J; Zhao X
    Stem Cell Res; 2020 Mar; 43():101699. PubMed ID: 31931472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A heterozygous MYH7 (c. 2156G > A) mutant human induced pluripotent stem cell line (ZZUNEUi020-A) generated from a patient with hypertrophic cardiomyopathy.
    Li X; Fu W; Guo G; Liu M; Du W; Zhao J; Liu Y; Wang L; Dong J; Zhao X
    Stem Cell Res; 2021 Mar; 51():102158. PubMed ID: 33453578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of an induced pluripotent stem cell line (ZJULLi003-A) from a hypertrophic cardiomyopathy patient carrying MYH7/c.4384G > A mutation.
    Zhou J; Sun Y; Wang H; Wang H; Guo F; Chen X; Gong T; Jiang C; Liang P
    Stem Cell Res; 2022 Oct; 64():102883. PubMed ID: 35944310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of three induced pluripotent stem cell lines from hypertrophic cardiomyopathy patients carrying MYH7 mutations.
    Cao X; Jahng JWS; Lee C; Zha Y; Wheeler MT; Sallam K; Wu JC
    Stem Cell Res; 2021 Aug; 55():102455. PubMed ID: 34352619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of two clonal iPSC lines, ICGi019-A and ICGi019-B, by reprogramming peripheral blood mononuclear cells of a patient suffering from hypertrophic cardiomyopathy and carrying a heterozygous p.M659I mutation in MYH7.
    Dementyeva EV; Kovalenko VR; Zhiven MK; Ustyantseva EI; Kretov EI; Vyatkin YV; Zakian SM
    Stem Cell Res; 2020 Jul; 46():101840. PubMed ID: 32422568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of two iPSC clones (MHHi021-A and MHHi021-B) from a patient with hypertrophic cardiomyopathy with p.Arg723Gly mutation in the MYH7 gene.
    Merkert S; Wunderlich S; Beier J; Franke A; Schwanke K; Göhring G; Kraft T; Francino A; Zweigerdt R; Martin U
    Stem Cell Res; 2021 Apr; 52():102208. PubMed ID: 33578365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of iPSC line from MYH7 R403L mutation carrier with severe hypertrophic cardiomyopathy and isogenic CRISPR/Cas9 corrected control.
    Fontaine V; Duboscq-Bidot L; Jouve C; Hamlin M; Curjol A; Briand V; Janiak P; Hulot JS; Pruniaux-Harnist MP; Charron P; Villard E
    Stem Cell Res; 2021 Apr; 52():102245. PubMed ID: 33610018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of two heterozygous MYBPC3 mutation-carrying human iPSC lines, SCVIi001-A and SCVIi002-A, for modeling hypertrophic cardiomyopathy.
    Liu L; Shenoy SP; Jahng JWS; Liu Y; Knowles JW; Zhuge Y; Wu JC
    Stem Cell Res; 2021 May; 53():102279. PubMed ID: 33743363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of induced pluripotent stem cells (iPSCs) from a hypertrophic cardiomyopathy patient with the pathogenic variant p.Val698Ala in beta-myosin heavy chain (MYH7) gene.
    Ross SB; Fraser ST; Nowak N; Semsarian C
    Stem Cell Res; 2017 Apr; 20():88-90. PubMed ID: 28395747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced myofilament calcium sensitivity aggravates abnormal calcium handling and diastolic dysfunction in patient-specific induced pluripotent stem cell-derived cardiomyocytes with MYH7 mutation.
    Guo G; Wang L; Li X; Fu W; Cao J; Zhang J; Liu Y; Liu M; Wang M; Zhao G; Zhao X; Zhou Y; Niu S; Liu G; Zhang Y; Dong J; Tao H; Zhao X
    Cell Calcium; 2024 Jan; 117():102822. PubMed ID: 38101154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients.
    Wu H; Yang H; Rhee JW; Zhang JZ; Lam CK; Sallam K; Chang ACY; Ma N; Lee J; Zhang H; Blau HM; Bers DM; Wu JC
    Eur Heart J; 2019 Dec; 40(45):3685-3695. PubMed ID: 31219556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of induced pluripotent stem cells from a patient with hypertrophic cardiomyopathy who carries the pathogenic myosin heavy chain 7 mutation p.Arg403Gln.
    Holliday M; Ross SB; Lim S; Mangala M; Hill A; Szappanos HC; Hool L; Semsarian C
    Stem Cell Res; 2018 Dec; 33():269-273. PubMed ID: 30508693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new common mutation in the cardiac beta-myosin heavy chain gene in Finnish patients with hypertrophic cardiomyopathy.
    Jääskeläinen P; Heliö T; Aalto-Setälä K; Kaartinen M; Ilveskoski E; Hämäläinen L; Melin J; Kärkkäinen S; Peuhkurinen K; Nieminen MS; Laakso M; ; Kuusisto J
    Ann Med; 2014 Sep; 46(6):424-9. PubMed ID: 24888384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of a human iPSC line ZZUNEUi015-A from a patient with hypertrophic cardiomyopathy caused by mutation in ALPK3.
    Tian X; Fu W; Guo G; Huang S; Dong Y; Li X; Dong J; Zhao X; Zhang Y
    Stem Cell Res; 2021 Apr; 52():102247. PubMed ID: 33607470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of an induced pluripotent stem cell line (ZJULLi004-A) from a hypertrophic cardiomyopathy patient carrying MYBPC3/c.3764C>A mutation.
    Sun Y; Zhou J; Wang H; Wang H; Chen X; Gong T; Liang P; Jiang C
    Stem Cell Res; 2022 Oct; 64():102898. PubMed ID: 36041398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptomatic distal myopathy with cardiomyopathy due to a MYH7 mutation.
    Overeem S; Schelhaas HJ; Blijham PJ; Grootscholten MI; ter Laak HJ; Timmermans J; van den Wijngaard A; Zwarts MJ
    Neuromuscul Disord; 2007 Jun; 17(6):490-3. PubMed ID: 17383184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells.
    Han L; Li Y; Tchao J; Kaplan AD; Lin B; Li Y; Mich-Basso J; Lis A; Hassan N; London B; Bett GC; Tobita K; Rasmusson RL; Yang L
    Cardiovasc Res; 2014 Nov; 104(2):258-69. PubMed ID: 25209314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incomplete-penetrant hypertrophic cardiomyopathy
    Lee S; Vander Roest AS; Blair CA; Kao K; Bremner SB; Childers MC; Pathak D; Heinrich P; Lee D; Chirikian O; Mohran SE; Roberts B; Smith JE; Jahng JW; Paik DT; Wu JC; Gunawardane RN; Ruppel KM; Mack DL; Pruitt BL; Regnier M; Wu SM; Spudich JA; Bernstein D
    Proc Natl Acad Sci U S A; 2024 May; 121(19):e2318413121. PubMed ID: 38683993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of an induced pluripotent stem cell line, ICGi029-A, by reprogramming peripheral blood mononuclear cells of a patient suffering from hypertrophic cardiomyopathy and carrying a heterozygous p.N515del mutation in MYBPC3.
    Dementyeva EV; Pavlova SV; Chernyavsky AM; Zakian SM
    Stem Cell Res; 2021 May; 53():102344. PubMed ID: 33892289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.